217
Oct 26 (Reuters) – Castle Biosciences Inc: * NEW DATA AT AMERICAN COLLEGE OF GASTROENTEROLOGY ANNUAL MEETING SHOW TISSUECYPHER® PROVIDES ACTIONABLE RISK INSIGHTS THAT INFLUENCE CLINICAL MANAGEMENT AND PROMPT RISK-ALIGNED INTERVENTION IN BARRETT’S ESOPHAGUS * CASTLE BIOSCIENCES INC – TISSUECYPHER SHOWS 34% AND 62% FIVE-YEAR PROGRESSION RISK Source text: Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
